Grufity logo
Grufity logo
FIXX

FIXX - Homology Medicines Inc Stock Price, Fair Value and News

$12.64-0.06 (-0.47%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

74/100

FIXX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

74/100

FIXX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FIXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FIXX Price Action

Last 7 days

-3.6%

Last 30 days

112.8%

Last 90 days

85.3%

Trailing 12 Months

643.5%

FIXX RSI Chart

FIXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FIXX Valuation

Market Cap

184.9M

Price/Earnings (Trailing)

5.56

Price/Sales (Trailing)

3.44

EV/EBITDA

4.24

Price/Free Cashflow

-6.75

FIXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FIXX Fundamentals

FIXX Revenue

Revenue (TTM)

53.7M

FIXX Earnings

Earnings (TTM)

33.3M

Earnings Growth (Yr)

31.1%

Earnings Growth (Qtr)

-113.16%

FIXX Profitability

EBT Margin

55.49%

Return on Equity

71.8%

Return on Assets

52.22%

Free Cashflow Yield

-14.82%

FIXX Investor Care

Shares Dilution (1Y)

19.94%

Diluted EPS (TTM)

2.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025---53.7M
20238.8M11.2M12.3M33.0M
20225.5M4.1M3.2M6.7M
202131.4M33.0M34.1M34.0M
20202.0M2.2M2.3M2.7M
20194.5M3.5M2.3M1.7M
2018---5.3M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Homology Medicines Inc

FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEhomologymedicines.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES92

Homology Medicines Inc Frequently Asked Questions

FIXX is the stock ticker symbol of Homology Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Homology Medicines Inc is 184.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, FIXX's PE ratio (Price to Earnings) is 5.56 and Price to Sales (PS) ratio is 3.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FIXX PE ratio will change depending on the future growth rate expectations of investors.